Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486981 | 0.79 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4477253 | 0.77 | DPP4 (0.50) | CNR1CNR2 | |
| SCHEMBL4559521 | 0.77 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL4512598 | 0.74 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2MAPTGRM5 | |
| SCHEMBL19835670 | 0.73 | ALDH1A1 (0.46) | ALDH1A1RXFP1MAPTTYRTSHR | |
| SCHEMBL5043907 | 0.70 | CNR1 (0.65) | ALDH1A1CNR1CNR2MARS1 | |
| SCHEMBL11081773 | 0.70 | MAPT (0.58) | ALDH1A1MAPTGRM5TYRTSHR | |
| SCHEMBL4424839 | 0.69 | CES2 (0.61) | ALDH1A1 | |
| SCHEMBL3814385 | 0.69 | DPP4 (0.40) | ALDH1A1RXFP1MAPTTYR | |
| SCHEMBL3267318 | 0.69 | CNR1 (0.45) | ALDH1A1RXFP1CNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618991-B2 | Heterocyclic derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1966173-A2 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068815-A2 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, NQO1 | ALDH1A1 181/4885RXFP1 389/4885CNR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.